In the screening for biological active compounds, the biotransformation processes catalyzed by filamentous fungi are useful because they can provide information about the possible appearance of toxic metabolites after oral administration and also generate new leads. In this paper, biotransformation of lapachol (1) by three fungal strains, Mucor circinelloides NRRL3631, Botrytis cinerea UCA992 and Botrytis cinerea 2100, has been investigated for the first time. Lapachol (1) was biotransformed into avicequinone-A (2) by M. circinelloides, 3'-hydroxylapachol (3) by B. cinerea, and into dehydro-α-lapachone (4) by both fungi. All these compounds were evaluated for their cytotoxic activities. The metabolite 2 displayed non-selective cytotoxicity against tumor and normal cell lines, 3 did not show cytotoxicity against the same cells, while 4 showed higher cytotoxicity against cancer cell lines than lapachol (1). The transformation of 1 into harmless and reactive metabolites evidences the importance of the evaluation of drug metabolism in the drug discovery process. Antifungal potential of lapachol (1) and its metabolites 2 and 4 against B. cinerea has also been evaluated. Dehydro-α-lapachone (4) has been shown to be less toxic to fungal growth than lapachol (1), which indicates a detoxification mechanism of the phytopathogen.
The biological activity of lapachol (1), a natural naphthoquinone, has been widely studied and includes: antibacterial activity against Mycobacterium tuberculosis and other microorganisms [1] , antiinflammatory [2] , molluscicidal [3] , antimalarial activity [4] , activity against Trypanossoma cruzi [5] and antioxidant activity [6] . Important studies regarding the antitumor properties of 1 have also been reported, but with serious side-effects in patients [7] . Today, the development of derivatives from 1 with improved bioactivity and fewer side-effects is sparking further studies [8, 9] .
Although several bioactivities of lapachol (1) have already been demonstrated, there are few studies about its metabolites. Bai and co-workers recently pointed out nine phase I and four phase II metabolites after in vivo metabolism of 1. Hydroxylation, semiquinone hydrogenation at the oxygen position, side chain rearrangement and glucuronidated conjugates formation were the main observed reactions [10] .
The natural product drug discovery process involves, among other approaches, the production of more active molecules by means of chemical or microbial transformations [11] . Microbial conversion has been widely used for the modification of bioactive natural products that are difficult to obtain by organic chemistry methods alone [12] .
The transformation of organic compounds by filamentous fungi is also important in predicting the metabolism that these chemicals could undergo after oral administration. In 1975, Smith and Rosazza [13] suggested that the metabolites from filamentous fungi are similar to those released in phase I (functionalization) or in phase II (conjugation) of xenobiotic modification by mammalian enzymes. The products of any xenobiotic metabolism may be: inactive metabolites with no pharmacological activity, named as detoxification products; active metabolites which may have pharmacological properties of less, equal, or greater magnitude than their parent compounds; or reactive metabolites that are capable of covalently reacting with the functional macromolecular structure of endogenous targets in vivo, resulting in undesired toxic effects [14] .
In this sense, metabolite elucidation in drug discovery is important in evaluating their safety and efficacy [15] . Reactive metabolite production from many conventional drugs and their toxic effects and/or adverse reactions to drugs has been extensively reported, including those from valproate [16] and diclofenac [17] . The importance of biotransformation in detoxification processes has also been reported [18] .
Given the pharmacological potential of lapachol (1) and the desire to find new derivatives with enhanced activity, research of the microbial metabolism of this compound could be an alternative tool to produce new drugs. The general aim of this work was to show that the filamentous fungi Mucor circinelloides and Botrytis cinerea are able to modify the structure of lapachol (1) and that this is useful in assessing the effects of microbial metabolism on drug performance and toxicity.
The incubation of lapachol (1) with the filamentous fungi M. circinelloides NRRL3631, B. cinerea BcUCA992 and B. cinerea Bc2100 for one day led to the isolation of three compounds. M. circinelloides biotransformed lapachol (1) into metabolites 2 and 4, while both strains of B. cinerea converted substrate 1 into products 3 and 4 ( Figure 1 ).
Spectroscopic data for structures 2, 3 and 4 coincided with those described in the literature for avicequinone-A (2) [19] , 3'hydroxylapachol (3) [20] and dehydro-α-lapachone (4) [21] .
Avicequinone-A (2) was reported as a component of Avicennia alba [19, 22] . According to Itoigawa et al. [22] , 2 displayed potent activity in studies of inhibitory effects on Epstein-Barr virus early antigen activation. 3´-Hydroxylapachol (3) had previously been reported as the main degradation product of β-lapachone in dark conditions [20] . Dehydro-α-lapachone (4), a natural compound with important biological activities [23] , was previously reported by us from biotransformation of 1 by human intestinal bacteria and the correlation of this process with the mammalian metabolism was highlighted [24] . Otten and Rosazza also isolated dehydro-αlapachone (4) from biotransformation of lapachol (1) by Curvularia lunata. The formation of 4 was suggested involving oxidative cyclization between C-2 and C-3 [25] .
Cell cytotoxicity assays were carried out with lapachol (1) and its metabolites avicequinone-A (2), 3´-hydroxylapachol (3) and dehydro-α-lapachone (4) on breast cancer cell line SKBR-3 and normal fibroblasts cell line GM07492-A. The IC 50 values against cell line SKBR-3 of 2 (IC 50 = 165.5 μmol L -1 ) and 1 (IC 50 = 72.3 μmol L -1 ), and against the normal cell line GM07402-A (IC 50 = 184.0 μmol L -1 for 2 and IC 50 = 835.0 μmol L -1 for 1) showed that 2 is less selective to cells than 1, indicating that 1 was biotransformed by M. circinelloides into the reactive metabolite 2. In contrast, the derivative 3 displayed no cytotoxic effect against either cell line. The derivative 4 was innocuous to normal cell lines, but showed higher activity against cancer cell lines (IC 50 = 10.3 µM L -1 ) than 1.
The IC 50 values of doxorubicin, used as positive control, were 0.45 and 7.00 µmol L -1 against breast cancer and normal fibroblasts cell lines, respectively.
Analysis of these results suggests the importance of the double bond in the pyran ring or in the alkyl chain on biological activity, since dehydro-α-lapachone (4) and lapachol (1) were more active than 3'hydroxylapachol (3) . The inhibition capacity of these compounds could give rise to further studies with a view to new drug leads.
Plant pathogens such as Botrytis cinerea are responsible for serious economic losses and there is a great need to develop novel fungicides, which have no harmful effects on crops or the environmental [26] . In light of the strong antifungal activity displayed by lapachol (1) against B. cinerea (IC 50 = 15.8 μmol L -1 for B. cinerea BcUCA992 and IC 50 = 6.0 μmol L -1 for B. cinerea Bc2100), we examined the inhibitory potential of the biotransformation products on the growth of the phytopathogenic fungus in order to identify a possible detoxification mechanism.
Unfortunately, there was not enough compound 3 to conduct the necessary antifungal bioassays, but the inhibitory effect of compounds 2 and 4 on B. cinerea growth was evaluated. Thus, avicequinone-A (2) showed IC 50 > 120 μmol L -1 for B. cinerea BcUCA992 and IC 50 = 76 μmol L -1 for B. cinerea Bc2100. The result obtained with dehydro-α-lapachone (4) showed IC 50 > 120 μmol L -1 against B. cinerea BcUCA992 and IC 50 = 33.0 μmol L -1 against B. cinerea Bc2100. The positive control (miconazol) showed IC 50 values of 0.5 μmol L -1 and 0.3 μmol L -1 against B. cinerea BcUCA992 and B. cinerea Bc2100, respectively.
Fungi are able to detoxify both synthetic and naturally occurring antifungal compounds producing degradation products less active against fungal growth than the parent compounds. B. cinerea is a good example of this [27] .
It is worth mentioning that all the compounds tested in this study behaved differently against the two strains of B. cinerea. In all cases, the inhibitory effect on the growth of B. cinerea Bc2100 was higher, revealing the genetic differences between both strains that could be associated with their adaptive lifestyles and their different host ranges [27] . The biotransformation products 2 and 4 were shown to be less toxic to fungal growth than lapachol (1), which indicates a detoxification mechanism of the fungus B. cinerea.
The biotransformation of lapachol (1) into harmless and reactive metabolites by the filamentous fungi M. circinelloides and B. cinerea, studied in this work for the first time, highlights the importance of biotransformation experiments as in vitro models to predict the metabolic fate of pharmaceuticals in mammalian systems. Furthermore, the antifungal activity of avicequinone-A (2) and dehydro-alpha-lapachone (4) against B. cinerea, and the interesting cytotoxic activity displayed by 4 and its high degree of selectivity to cancer cell lines, underscores the usefulness of the biotransformation approach in the development of active compounds.
Experimental
General: 1 When the microorganisms were transferred to liquid media, 3 mg of lapachol (1) dissolved in 600 µL of dimethyl sulfoxide (DMSO) were added to each Erlenmeyer flask. All flasks were incubated for an additional 5 days with shaking (120 rpm) at 30°C. Samples were taken every day. Control flasks consisted of culture medium with fungi and DMSO without substrate, and culture medium with 1 solubilized in DMSO without fungi.
After the fermentation period, the samples were separately processed. The mycelium was filtered and then washed with brine. The broths were extracted 3 times with ethyl acetate and the extract dried over anhydrous sodium sulfate. The solvent was then evaporated and the residue submitted to TLC analyses. After this, the samples were chromatographed, first on a silica gel column and then by HPLC with an increasing gradient of ethyl acetate to nhexane.
Chromatography of the combined extracts fermented by M. circinelloides gave avicequinone-A (2) (1.0 mg) and dehydro-αlapachone (4) 
Antifungal assay:
The lowest concentration of lapachol (1), avicequinone-A (2) and dehydro-α-lapachone (4) capable of inhibiting microorganism growth (MIC, minimal inhibitory concentration) was determined in triplicate by using the microdilution broth method in 96-well microplates [19] . The strains of the microorganisms used in this work were Botrytis cinerea Bc2100 and B. cinerea BcUCA992. Samples were dissolved in dimethyl sulfoxide (DMSO) at 12.5 mg mL -1 , followed by dilution in Sabourad-Glucose and concentrations ranging from 250 to 0.5 ppm were achieved. The final DMSO content was 2%, v/v, and this solution was used as the negative control. The inoculum was adjusted for each organism to yield a cell concentration of 5 × 10 4 spores mL -1 . One inoculated well was included to check the appropriateness of the broth for organism growth. One noninoculated well, free of any antimicrobial agent, was also employed to ensure medium sterility. Miconazol was used as the positive control. The microplates (96 wells) were incubated at 30°C for 72 h. The inhibition percentage and IC 50 values were calculated for each microorganism [28] .
Supplementary data: 1 H, 13 C, HMQC and HMBC NMR spectra for compounds 2, 3 and 4 are available.
